Rafferty Asset Management
ALNY icon

Rafferty Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Rafferty Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.7M Buy
55,332
+4,779
+9% +$1.44M 0.04% 201
2026
Q1 		$16.7M Buy
50,553
+5,522
+12% +$1.88M 0.07% 161
2025
Q4 		$17.9M Buy
45,031
+27,880
+163% +$12.3M 0.06% 170
2025
Q3 		$7.82M Sell
17,151
-15,045
-47% -$6.13M 0.03% 334
2025
Q2 		$10.5M Sell
32,196
-12,389
-28% -$3.43M 0.03% 260
2025
Q1 		$12M Sell
44,585
-8,232
-16% -$2.12M 0.05% 226
2024
Q4 		$12.4M Sell
52,817
-11,014
-17% -$2.9M 0.04% 249
2024
Q3 		$17.6M Sell
63,831
-17,279
-21% -$4.5M 0.06% 170
2024
Q2 		$19.7M Buy
81,110
+19,904
+33% +$3.14M 0.07% 146
2024
Q1 		$9.15M Buy
61,206
+8,398
+16% +$1.4M 0.03% 295
2023
Q4 		$10.1M Buy
52,808
+8,640
+20% +$1.47M 0.04% 276
2023
Q3 		$7.82M Buy
44,168
+615
+1% +$117K 0.05% 290
2023
Q2 		$8.27M Buy
43,553
+5,362
+14% +$1.06M 0.05% 257
2023
Q1 		$7.65M Buy
38,191
+1,888
+5% +$397K 0.05% 256
2022
Q4 		$8.63M Buy
36,303
+3,411
+10% +$728K 0.07% 229
2022
Q3 		$6.58M Buy
32,892
+1,702
+5% +$325K 0.07% 244
2022
Q2 		$4.55M Sell
31,190
-5,845
-16% -$829K 0.04% 295
2022
Q1 		$6.05M Buy
37,035
+5,090
+16% +$775K 0.04% 326
2021
Q4 		$5.42M Buy
31,945
+15,515
+94% +$2.88M 0.03% 360
2021
Q3 		$3.1M Buy
16,430
+621
+4% +$116K 0.02% 457
2021
Q2 		$2.68M Sell
15,809
-7,619
-33% -$1.12M 0.02% 549
2021
Q1 		$3.31M Buy
23,428
+16,239
+226% +$2.44M 0.02% 424
2020
Q4 		$934K Sell
7,189
-9,017
-56% -$1.2M 0.01% 520
2020
Q3 		$2.36M Buy
16,206
+6,263
+63% +$890K 0.03% 368
2020
Q2 		$1.47M Buy
9,943
+5,863
+144% +$790K 0.02% 434
2020
Q1 		$444K Sell
4,080
-29,417
-88% -$3.4M 0.02% 357
2019
Q4 		$3.86M Sell
33,497
-44,138
-57% -$4.4M 0.06% 172
2019
Q3 		$6.24M Buy
77,635
+6,858
+10% +$543K 0.1% 121
2019
Q2 		$5.14M Buy
70,777
+11,052
+19% +$848K 0.09% 160
2019
Q1 		$5.58M Buy
+59,725
New +$5M 0.09% 120

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rafferty Asset Management's ALNY Position: Q2 2026 in Review

Rafferty Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 9.5% in Q2 2026, buying an estimated $1.44M and bringing the position to 55,332 shares worth $16.7M. The position accounts for 0.04% of the portfolio, ranked #201.

Rafferty Asset Management first reported a position in ALNY in Q1 2019 and has held it in 30 quarters since. The position peaked at $19.7M in Q2 2024. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Rafferty Asset Management held 55,332 shares of Alnylam Pharmaceuticals worth $16.7M as of Q2 2026.
  • Rafferty Asset Management bought 4,779 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
  • Alnylam Pharmaceuticals made up 0.04% of Rafferty Asset Management's portfolio in Q2 2026, its #201 holding.
  • Rafferty Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2019 and has held it in 30 quarters since.
  • Rafferty Asset Management's Alnylam Pharmaceuticals position peaked at $19.7M in Q2 2024.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.